INTERIM UPDATE
CommitteeOpinion2017
Number 767
(Replaces Committee Opinion Number 692, September 2017)


Committee on Obstetric Practice
This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice in collaboration with committee members Yasser Y. El-Sayed, MD, and Ann E. Borders, MD, MSc, MPH.

This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.


INTERIM UPDATE: This Committee Opinion is updated as highlighted to align with the American College of Obstetricians and Gynecologists’ guidance on gestational hypertension, preeclampsia, and chronic hypertension in pregnancy.


PDF Format

Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

ABSTRACT: Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to initiate the prompt administration of medication when a patient presents with a hypertensive emergency. Treatment with first-line agents should be expeditious and occur as soon as possible within 30–60 minutes of confirmed severe hypertension to reduce the risk of maternal stroke. Intravenous labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period. Although relatively less information currently exists for the use of calcium channel blockers for this clinical indication, the available evidence suggests that immediate release oral nifedipine also may be considered as a first-line therapy, particularly when intravenous access is not available. In the rare circumstance that intravenous bolus labetalol, hydralazine, or immediate release oral nifedipine fails to relieve acute-onset, severe hypertension and is given in successive appropriate doses, emergent consultation with an anesthesiologist, maternal–fetal medicine subspecialist, or critical care subspecialist to discuss second-line intervention is recommended.


Recommendations and Conclusions

The American College of Obstetricians and Gynecologists makes the following recommendations and conclusions:

  • Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes.
  • Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy.
  • Close maternal and fetal monitoring by a physician and nursing staff are advised during the treatment of acute-onset, severe hypertension.
  • After initial stabilization, the team should monitor blood pressure closely and institute maintenance therapy as needed.
  • Intravenous (IV) labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period.
  • Immediate release oral nifedipine also may be considered as a first-line therapy, particularly when IV access is not available.
  • The use of IV labetalol, IV hydralazine, or immediate release oral nifedipine for the treatment of acute-onset, severe hypertension for pregnant or postpartum patients does not require cardiac monitoring.
  • In the rare circumstance that IV bolus labetalol, hydralazine, or immediate release oral nifedipine fails to relieve acute-onset, severe hypertension and is given in successive appropriate doses, emergent consultation with an anesthesiologist, maternal–fetal medicine subspecialist, or critical care subspecialist to discuss second-line intervention is recommended.
  • Magnesium sulfate is not recommended as an antihypertensive agent, but magnesium sulfate remains the drug of choice for seizure prophylaxis for women with acute-onset severe hypertension during pregnancy and the postpartum period. Starting magnesium should not be delayed in the setting of acute severe hypertension; it is recommended regardless of whether the patient has gestational hypertension with severe features, preeclampsia with severe features, or eclampsia.

Risk reduction and successful, safe clinical outcomes for women with preeclampsia or eclampsia require appropriate and prompt management of severe systolic and severe diastolic hypertension (1). Integrating standardized order sets into everyday safe practice in the United States is a challenge. Increasing evidence indicates that standardization of care improves patient outcomes (2). Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes (3, 4). With the advent of pregnancy hypertension guidelines in the United Kingdom, care of maternity patients with preeclampsia or eclampsia improved significantly, and maternal mortality rates decreased because of a reduction in cerebral and respiratory complications (5, 6). Individuals and institutions should have mechanisms in place to initiate the prompt administration of medication when a patient presents with a hypertensive emergency. Treatment with first-line agents should be expeditious and occur as soon as possible within 30–60 minutes of confirmed severe hypertension (blood pressure greater than 160/110 mm Hg and persistent for 15 minutes) to reduce the risk of maternal stroke (7–9). The use of checklists may be a useful tool to facilitate this process. This document revises Committee Opinion Number 623, Emergent Therapy for Acute-Onset, Severe Hypertension with Preeclampsia or Eclampsia, primarily to clarify the terminology around immediate release oral nifedipine and to clarify monitoring expectations during and after treatment of acute-onset, severe hypertension.

Acute-onset, severe systolic (greater than or equal to 160 mm Hg) hypertension; severe diastolic (greater than or equal to 110 mm Hg) hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. These conditions can occur in the second half of gestation in women not known to have chronic hypertension who develop sudden, severe hypertension (ie, with preeclampsia; gestational hypertension; or hemolysis, elevated liver enzymes, and low platelet count [HELLP] syndrome), but they also can occur among patients with chronic hypertension who are developing superimposed preeclampsia or a hypertensive exacerbation with acutely worsening, difficult to control, severe hypertension.

Acute-onset, severe hypertension that is accurately measured using standard techniques and is persistent for 15 minutes or more is considered a hypertensive emergency. It is well known that severe hypertension can cause central nervous system injury. As stated in the Confidential Enquiries report from the United Kingdom, two thirds of the maternal deaths during 2003–2005 resulted from cerebral hemorrhage or infarction (5). The degree of systolic hypertension (as opposed to the level of diastolic hypertension or relative increase or rate of increase of mean arterial pressure from baseline levels) may be the most important predictor of cerebral injury and infarction. In a case series of 28 women with preeclampsia with severe features and stroke, all but one woman had severe systolic hypertension just before a hemorrhagic stroke, and 54% died, whereas only 13% had severe diastolic hypertension in the hours preceding a stroke (10). A similar relationship between severe systolic hypertension and risk of hemorrhagic stroke has been observed in nonpregnant adults (11). Thus, systolic blood pressure (BP) of 160 mm Hg or greater should be included as part of the definition of severe hypertension in pregnant women or women in the postpartum period (12).

Accurate measurement of blood pressure is necessary to optimally manage hypertension in pregnancy. Standardized protocols to measure BP in pregnant patients facilitate accuracy and ensure that appropriate steps are followed across all units regardless of patient arm size or shape. Mercury sphygmomanometer is considered the gold standard; however, validated equivalent automated equipment also can be used. It is necessary to obtain the correct cuff size (a range of cuff sizes with directions to determine appropriate cuff size based on arm shape should be available) and patients should be positioned in a sitting or semireclining position with the back supported. Patients should not be repositioned to reclining or be on their sides in order to obtain a lower BP because it will provide a false reading (see the California Maternal Quality Care Collaborative Toolkit for standardized protocol for a BP measurement example) (13).

Pregnant women, or women in the postpartum period, with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. The goal is not to normalize BP, but to achieve a range of 140–150/90–100 mm Hg in order to prevent repeated, prolonged exposure to severe systolic hypertension, with subsequent loss of cerebral vasculature autoregulation. In the event of a hypertensive crisis, with prolonged uncontrolled hypertension, maternal stabilization should occur before delivery, even in urgent circumstances (14). When acute-onset, severe hypertension is diagnosed in the office setting, the patient should be expeditiously sent to the hospital for treatment. Also, if transfer to a tertiary center is likely (eg, for preterm preeclampsia with severe features), BP should be stabilized and other measures initiated as appropriate, such as magnesium sulfate for seizure prophylaxis, before transfer.

Endotracheal intubation is another risk of severe hypertension and is well known to increase BP sometimes to severe levels that require emergent therapeutic intervention (14). Induction of general anesthesia and intubation should never be undertaken without first taking steps to eliminate or minimize the hypertensive response to intubation. Close maternal and fetal monitoring by a physician and nursing staff are advised during the treatment of acute-onset, severe hypertension, and judicious fluid administration is recommended even in the case of oliguria. After initial stabilization, the team should monitor BP closely and institute maintenance therapy as needed.

First-line Therapy

Intravenous labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period. Although relatively less information currently exists for the use of calcium channel blockers for this clinical indication, the available evidence suggests that immediate release oral nifedipine also may be considered as a first-line therapy (15–18), particularly when IV access is not available. Some studies have shown that women who received immediate release oral nifedipine had their BP lowered more quickly than with either IV labetalol or hydralazine and had a significant increase in urine output (15, 19). Concern for neuromuscular blockade and severe hypotension with the contemporaneous use of nifedipine and magnesium sulfate were not substantiated in a large retrospective review (20). However, because both drugs are calcium antagonists, facilities should be prepared to monitor maternal vital signs (see Box 1), with attention to normal heart rate and blood pressure. Immediate release oral nifedipine capsules should be administered orally and not punctured or otherwise administered sublingually.

Patients may respond to one drug and not another. Magnesium sulfate is not recommended as an antihypertensive agent, but magnesium sulfate remains the drug of choice for seizure prophylaxis for women with acute-onset severe hypertension during pregnancy and the postpartum period. Starting magnesium should not be delayed in the setting of acute severe hypertension; it is recommended regardless of whether the patient has gestational hypertension with severe features, preeclampsia with severe features, or eclampsia. Box 1, Box 2, and Box 3 outline sample order sets for the use of IV labetalol, IV hydralazine, and immediate release oral nifedipine for the initial management of acute-onset, severe hypertension in women who are pregnant or in the postpartum period (15–17, 19, 21).

It is important to note differences in recommended dosage intervals between these options, which reflect differences in their pharmacokinetics. Although all three medications are appropriately used for the treatment of hypertensive emergencies in pregnancy, each agent can be associated with adverse effects. Parenteral hydralazine may increase the risk of maternal hypotension (systolic BP, 90 mm Hg or less) (22). Parenteral labetalol may cause neonatal bradycardia and should be avoided in women with asthma, heart disease, or congestive heart failure (23, 24). Nifedipine has been associated with an increase in maternal heart rate, and less risk of overshoot hypotension (15). No significant changes in umbilical blood flow have been observed with the use of either labetalol or hydralazine (25), and maternal and perinatal outcomes are similar for both drugs (18). Likewise, no significant changes in the uteroplacental blood flow or the fetal heart have been noted with the use of immediate release oral nifedipine for treatment of severe pregnancy-induced hypertension (26–28). Immediate release oral nifedipine should not be given sublingually because of risk of hypotension.

Box 1

The use of IV labetalol, IV hydralazine, or immediate release oral nifedipine for the treatment of acute-onset, severe hypertension for pregnant or postpartum patients does not require cardiac monitoring or other special monitoring beyond that which is outlined in the order sets in this document (see Box 1, Box 2, Box 3), which describe time intervals for repeat vital sign assessment and escalation of therapy. In addition, personnel in all hospital settings, including labor and delivery, antepartum, postpartum, and emergency department units, should be able to provide these initial medications without transferring patients to another unit. Protocols that include additional requirements in order to provide urgent IV hypertension therapy lead to unnecessary delays in treatment for severe hypertension for pregnant and postpartum patients. Hospital protocols should be updated in order to reflect current recommended order sets (see, for example, Box 1, Box 2, Box 3) and, therefore, optimize time to appropriate therapy for all pregnant and postpartum patients with acute-onset, severe hypertension.

Box 2 Box 3

When treatment for acute-onset, severe hypertension is needed and IV access has not yet been initiated, a 200-mg dose of labetalol can be administered orally if immediate release oral nifedipine is not available. This labetalol dose may be repeated in 30 minutes if appropriate improvement is not observed (6). The immediate release oral nifedipine algorithm should be first-line therapy in this setting when IV access is not available or not yet obtained.

Treatment of Resistant Hypertension

In the rare circumstance that IV bolus labetalol, hydralazine, or immediate release oral nifedipine fails to relieve acute-onset, severe hypertension and is given in successive appropriate doses, such as those outlined in the order sets (see Box 1, Box 2, and Box 3), emergent consultation with an anesthesiologist, maternal–fetal medicine subspecialist, or critical care subspecialist to discuss second-line intervention is recommended. Second-line alternatives to consider include nicardipine or esmolol by infusion pump (29–31).

Sodium nitroprusside should be reserved for extreme emergencies and used for the shortest amount of time possible because of concerns about cyanide and thiocyanate toxicity in the woman and fetus or newborn, and increased intracranial pressure with potential worsening of cerebral edema in the woman (21). Once the hypertensive emergency is treated, a complete and detailed evaluation of maternal and fetal well-being is needed with consideration of, among many issues, the need for subsequent pharmacotherapy and the appropriate timing of delivery.

For More Information

The American College of Obstetricians and Gynecologists has identified additional resources on topics related to this document that may be helpful for ob-gyns, other health care providers, and patients. You may view these resources at www.acog.org/More-Info/HypertensionInPregnancy.

These resources are for information only and are not meant to be comprehensive. Referral to these resources does not imply the American College of Obstetricians and Gynecologists’ endorsement of the organization, the organization’s website, or the content of the resource. The resources may change without notice.

References

  1. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.
  2. Kirkpatrick DH, Burkman RT. Does standardization of care through clinical guidelines improve outcomes and reduce medical liability? Obstet Gynecol 2010;116:1022–6.
  3. Menzies J, Magee LA, Li J, MacNab YC, Yin R, Stuart H, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Preeclampsia Integrated Estimate of RiSk (PIERS) Study Group. Obstet Gynecol 2007;110:121–7.
  4. von Dadelszen P, Sawchuck D, McMaster R, Douglas MJ, Lee SK, Saunders S, et al. The active implementation of pregnancy hypertension guidelines in British Columbia. Translating Evidence-Based Surveillance and Treatment Strategies (TESS) Group. Obstet Gynecol 2010;116:659–66.
  5. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(suppl 1):1–203.
  6. Tuffnell DJ, Jankowicz D, Lindow SW, Lyons G, Mason GC, Russell IF, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. Yorkshire Obstetric Critical Care Group. BJOG 2005;112:875–80.
  7. Clark SL, Hankins GD. Preventing maternal death: 10 clinical diamonds. Obstet Gynecol 2012;119:360–4.
  8. Druzin ML, Shields LE, Peterson NL, Cape V. Improving health care response to preeclampsia: a California quality improvement toolkit [after login]. Stanford (CA): California Maternal Quality Care Collaborative; 2013. Available at: https://www.cmqcc.org/resources-tool-kits/toolkits/preeclampsia-toolkit. Retrieved December 12, 2016.
  9. Council on Patient Safety in Women’s Health Care. Patient safety bundle: hypertension. Washington, DC: American College of Obstetricians and Gynecologists; 2015. Available at: http://safehealthcareforeverywoman.org/wp-content/uploads/2016/09/Hypertension-Bundle-Final-05-14-15.pdf. Retrieved December 12, 2016.
  10. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005;105:246–54.
  11. Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. Am J Epidemiol 1995;142:1279–90.
  12. Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Hypertension Guideline Committee; Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. J Obstet Gynaecol Can 2008;30:S1–48.
  13. Gabel K. Patient care and treatment recommendations: accurate blood pressure measurement [after login]. Stanford (CA): California Maternal Quality Care Collaborative; 2013. Available at: https://www.cmqcc.org/resource/accurate-blood-pressure-measurement-toolkit-pdf. Retrieved February 17, 2017.
  14. Lyons G. Saving mothers’ lives: confidential enquiry into maternal and child health 2003–5. Int J Obstet Anesth 2008;17:103–5.
  15. Vermillion ST, Scardo JA, Newman RB, Chauhan SP. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol 1999;181:858–61.
  16. Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG 2012;119:78–85.
  17. Shekhar S, Sharma C, Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol 2013;122:1057–63.
  18. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD001449. DOI: 10.1002/14651858.CD001449.pub3.
  19. Rezaei Z, Sharbaf FR, Pourmojieb M, Youefzadeh-Fard Y, Motevalian M, Khazaeipour Z, et al. Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. Acta Med Iran 2011;49:701–6.
  20. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193:153–63.
  21. National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 04-5230. Bethesda (MD): NHLBI; 2004. Available at: https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf. Retrieved December 5, 2016.
  22. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1–S22.
  23. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955–60.
  24. Magee LA, von Dadelszen P. The management of severe hypertension. Semin Perinatol 2009;33:138–42.
  25. Baggio MR, Martins WP, Calderon AC, Berezowski AT, Marcolin AC, Duarte G, et al. Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. Ultrasound Med Biol 2011;37:53–8.
  26. Lurie S, Fenakel K, Friedman A. Effect of nifedipine on fetal heart rate in the treatment of severe pregnancy-induced hypertension. Am J Perinatol 1990;7:285–6.
  27. Scardo JA, Vermillion ST, Hogg BB, Newman RB. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996;175:336–8; discussion 338–40.
  28. Moretti MM, Fairlie FM, Akl S, Khoury AD, Sibai BM. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol 1990;163:1844–8.
  29. Labetalol hydrochloride—oral. In: Drug facts and comparisons. 2016 ed. St. Louis (MO): Wolters Kluwer; 2016. p. 884–7.
  30. Vadhera RB, Pacheco LD, Hankins GD. Acute antihypertensive therapy in pregnancy-induced hypertension: is nicardipine the answer? Am J Perinatol 2009;26:495–9.
  31. Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv 2010;65:341–7.

Published online on December 20, 2018.

Copyright 2018 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Requests for authorization to make photocopies should be directed to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400.

American College of Obstetricians and Gynecologists
409 12th Street, SW, PO Box 96920, Washington, DC 20090-6920

Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee Opinion No. 767. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e174–80.

American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188
Mailing Address: PO Box 96920, Washington, DC 20024-9998